Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Spero Therapeutics Inc. SPRO

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare,...

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:SPRO)

Fundamentals Snapshot (NDAQ:SPRO)

Current News (NDAQ:SPRO)

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

GlobeNewswire 8 days ago

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

GlobeNewswire September 15, 2022

Spero Therapeutics to Present at Upcoming Investor Conference

GlobeNewswire September 7, 2022

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

GlobeNewswire September 6, 2022

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

GlobeNewswire August 10, 2022

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

GlobeNewswire August 9, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 25, 2022 in Spero Lawsuit - SPRO

Newsfile July 25, 2022

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

PR Newswire July 25, 2022

SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class Action - SPRO

Newsfile July 25, 2022

Opinion & Analysis (NDAQ:SPRO)

No current opinion is available.

Bullboard Posts (NDAQ:SPRO)

SPRO ....can'y win em all

Iseneschal - 8 days ago

SPRO ..... watching for Volume increase and Price Action

Might run again....currently at ~$2.40
Iseneschal - 8 days ago

SPRO .... In PB mode

Stops save portfolios....just sayin ; ) Next support...... ~ $2.11  JMHO
Iseneschal - 8 days ago

SPRO .....vols are decreasing and.....

Price action is "sideways" ....or in other words "Range Bound" Me no position Still on watch
Iseneschal - 8 days ago

SPRO ...... I managed to get another small position

just before this big rally into the gap I have a habit of " taking profits way too early" Sold it over $2.60 Watching &...
Iseneschal - 8 days ago

SPRO ...... Now into "The Gap"

Next resistance is $4.65 ..... I stand corrected
Iseneschal - 8 days ago